Chenodeoxycholic acid and taurochenodexycholic acid induce anti-apoptotic cIAP-1 expression in human hepatocytes

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 12, 2006, Pages 1807-1813

  Hirano, Fuminori ^a   Haneda, Masakazu ^a   Makino, Isao ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b Hokushinkai Megumino Hospital   (Japan)

Author keywords

Apoptosis; Bile acid; Chenodeoxycholic acid; cIAP 1; Nuclear factor B

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BILE ACID; CALPHOSTIN C; CHENODEOXYCHOLIC ACID; GLYCOCHENODEOXYCHOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; TAUROCHENODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID; WORTMANNIN; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FETUS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 33750474132     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04363.x     Document Type: Article

References (42)

1. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (1). N. Engl. J. Med. 1989; 321: 1014-22.
2. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N. Engl. J. Med. 1998; 339: 1217-27.
3. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003; 362: 53-61.
4. Schmucker DL, Ohta M, Kanai S et al. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990; 12: 1216-21.
5. Heuman DM, Mills AS, McCall J et al. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991; 100: 203-11.
6. Hofmann AF. Cholestatic liver disease: pathophysiology and therapeutic options. Liver 2002; 22 (Suppl. 2): 14-19.
7. Patel T, Bronk SF, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J. Clin. Invest. 1994; 94: 2183-92.
8. Yerushalmi B, Dahl R, Devereaux MW et al. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 2001; 33: 616-26.
9. Lieser MJ, Park J, Natori S et al. Cholestasis confers resistance to the rat liver mitochondrial permeability transition. Gastroenterology 1998; 115: 693-701.
10. Faubion WA, Guicciardi ME, Miyoshi H et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 1999; 103: 137-45.
11. Azzaroli F, Mehal W, Soroka CJ et al. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 2002; 36: 49-54.
12. Qiao L, Studer E, Leach K et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol. Biol. Cell 2001; 12: 2629-45.
13. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 1999; 159: 2647-58.
14. Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267: 2003-6.
15. Rust C, Karnitz LM, Paya CV et al. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 2000; 275: 20210-16.
16. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat. Immunol. 2002; 3: 221-7.
17. Green DR. Death and NF-κB in T cell activation: life at the edge. Mol. Cell 2003; 11: 551-2.
18. Schoemaker MH, Gommans WM, de la Rosa LC et al. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-κB activation. J. Hepatol. 2003; 39: 153-61.
19. Wang CY, Mayo MW, Korneluk RG et al. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-3.
20. Stehlik C, de Martin R, Kumabashiri I et al. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J. Exp. Med. 1998; 188: 211-16.
21. Erl W, Hansson GK, de Martin R et al. Nuclear factor-κB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ. Res. 1999; 84: 668-77.
22. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell. Biol. 2002; 3: 401-10.
23. Hirano F, Kobayashi A, Hirano Y et al. Bile acids regulate RANTES gene expression through its cognate NF-κB binding sites. Biochem. Biophys. Res. Commun. 2001; 16: 1095-101.
24. Batta AK, Arora R, Salen G et al. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J. Lipid Res. 1989; 30: 1953-62.
25. Stiehl A, Rudolph G, Raedsch R et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990; 12: 492-7.
26. Crosignani A, Podda M, Battezzati PM et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14: 1000-7.
27. Jazrawi RP, Caestecker JS, Goggin PM et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106: 134-42.
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156-9.
29. Hirano F, Komura K, Fukawa E et al. Tumor necrosis factor α (TNF-α) -induced RANTES chemokine expression via activation of NF-κB and p38 MAP kinase: roles of TNF-α in alcoholic liver diseases. J. Hepatol. 2003; 38: 483-9.
30. Hirano F, Chung M, Tanaka H et al. Alternative splicing variants of IκBβ establish differential NF-κB signal responsiveness in human cells. Mol. Cell. Biol. 1998; 18: 2596-07.
31. Hirano Y, Hirano F, Fujii H et al. Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-κB activation. Eur. J. Pharmacol. 2002; 448: 19-26.
32. Qiao L, Yacoub A, Studer E et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 2002; 35: 779-89.
33. Widmann C, Gibson S, Jarpe MB et al. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999; 79: 143-80.
34. Han J, Lee JD, Bibbs L et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265: 808-11.
35. Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis 2001; 22: 35-41.
36. MAPK activation and translocation of the bile salt export pump in rats. Gastroenterology 2001; 121: 407-19.
37. Yoon JH, Higuchi H, Werneburg NW et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002; 122: 985-93.
38. Grambihler A, Higuchi H, Bronk SF et al. cFLIP-L inhibits p38 MAPK activation: an additional anti-apoptotic mechanism in bile acid-mediated apoptosis. J. Biol. Chem. 2003; 278: 26831-7.
39. Graf D, Reinehr R, Kurz AK et al. Inhibition of taurolithocholate 3-sulfate-induced apoptosis by cyclic AMP in rat hepatocytes involves protein kinase A-dependent and -independent mechanisms. Arch. Biochem. Biophys. 2003; 415: 34-42.
40. Goebeler M, Gillitzer R, Kilian K et al. Multiple signaling pathways regulate NF-κB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood 2001; 97: 46-55.
41. Craig R, Larkin A, Mingo AM et al. p38 MAPK and NF-κB collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J. Biol. Chem. 2000; 275: 23814-24.
42. Chae HJ, Chae SW, Chin HY et al. The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts. Bone 2001; 28: 45-53.